source
- STAT roundup highlights obesity drug competition and other ADA conference updatesSTAT's ADA in 30 Seconds newsletter offers a brief snapshot of the American Diabetes Association's annual meeting, covering a range of topics for readers. Elaine Chen notes that the market for obe…
- Pfizer's Berobenatide GLP-1 injection shows efficacy in obesity and diabetes in early dataPfizer presented early data on its long-acting GLP-1 injection, Berobenatide, at a conference on June 6, 2026. The results indicated the drug was effective in patients who have both obesity and d…